{"name":"Syros Pharmaceuticals","slug":"syros","ticker":"SYRS","exchange":"NASDAQ","domain":"syros.com","description":"Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"68","ceo":"Nancy Simonian","sector":"Oncology / Hematology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$5,366","metrics":{"revenue":1982000,"revenueGrowth":290.2,"grossMargin":0,"rdSpend":108153000,"netIncome":-164574000,"cash":58275000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Tamoxifen patent cliff ($0.0B at risk)","drug":"Tamoxifen","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Syros Pharmaceuticals Announces FDA Clearance of Investigational New Drug (IND) Application for SY-5609","summary":"Syros Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for SY-5609, a selective inhibitor of the CD73 enzyme.","drugName":"SY-5609","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Syros Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Syros Pharmaceuticals reported its financial results for the third quarter of 2023, with a net loss of $34.5 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Syros Pharmaceuticals Announces Collaboration with Merck KGaA to Develop Novel Cancer Therapies","summary":"Syros Pharmaceuticals announced a collaboration with Merck KGaA to develop novel cancer therapies using Syros' gene control platform.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPSkVlT3E1bVVIZHk2dFhzN0JSYVVNMENFYlQ5eWlqN0JxV3NHa0JnMkNBalctcWRCTVdOa1Q4RlFyalpLM3FOdzVBdGNXUWY0SzdrR202UjFqM2gtU2x1RXJrTWFuWDY4Y0doQllqTlh1eHpnY2VUTEM3LVJ4bEJiM0xMbkNfaU5yWnlxem80RXkwdExuaUtiMFRyNVE4dm5vaDRfUnpHNGtGWkZDbHluOWtYLUEzRTMtU1E?oc=5","date":"2025-04-15","type":"deal","source":"GuruFocus","summary":"Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus","headline":"Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMlc3VnBOMmtwdF9RTXhVWUxrVEQ1OXQ1MWJYYlU1bVFwNlJyLUU3VTk5NWN1WVM4dUU3QWZXc0I0STZoZENFVGNSRXVsR21GcXBhNGwwNVpIQ2pfVVdTLVNnVzBQaEpaWG1uVWtlMXMwMG9xeE1SaThrVGRpMU92OUdxTU5TaW9XTjhfSGF4amVRcjY5NzFsYS1kSzZGYTRCNGhHWHFCV2pUek5YbkRtbUxNNm85cy1kNnVyMXVEUVY0NHRaOEpXMDg2U0hrRUJmZUdsUFZtdFdtSllGblVBcEV0X0FlYXhibkE?oc=5","date":"2025-04-15","type":"trial","source":"PR Newswire","summary":"Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - PR Newswire","headline":"Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQLWR2aExBZjJwVUk1Z2c1b1VhLWtMZnU3WTBHc2RwX3ptbzJ1S2xLVTl1LVBIQ21RRnloZjBycFh4UDBhb2laVVZQVjN1dk5NamxZM1E1MU1EWFZfUW9ERWtoMFdVYTFtaGwwc1FPSzRodkdVVXFkZ3lpdl83TGUzUGlUblE1elhtajlucG1EckZ4SC16THVQdXNZNk8xN3dwMHVhem94TEk2SkVZMHI4?oc=5","date":"2025-03-04","type":"pipeline","source":"Investing.com","summary":"Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com","headline":"Syros Pharmaceuticals settles debt with Oxford Finance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNMFpZUFlBbzdLMFdWV0RZZWhfTjRib2xxcXZBWmV2bVk3VnFkcEdvaW54ZnlvMEVIQl9BcVRhRmVsa3YzeFdvU1pHbWc5RXFRbEx6RHFYRXZJZ3FtdDZTbld2dDdMMzktVERQZTZPUnd2ckZ4NTQ4aDlkbk16UjJHZk9NelNfcUFER0hLak9PUnJkUEVFbmxqT093dHF1OGZlaGd6MkM2b3h2dE5BcTE4?oc=5","date":"2025-02-28","type":"trial","source":"Stock Titan","summary":"Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan","headline":"Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOR1plRndJV2lLZ3FPT1Q1SHR0Q0Z0aGx6ZTJtV2pSNFZlYzJ6N1pUYU5QNFh3ZmVSVkJFWERuc0REWWs5b1hiX1g1Tjh1MGgySk15aExHdHQ4NGJEZG82VWk2T0YzLWhZT0NuUWxYS1dFSzM3ZzZZNmVJYU8tQnFvUEdnb3UwZ19uWEd2T3BIM2F0V2dtOHpKWDNyZjZwMnh5eTlYOV9FSndmdFZzZGdwZC1ZVlVhX2xXOXVKRGQ1TC1hQmxsQ2h3aGk4ZXBXZ0NYWVdSMFJDVU93bVI4RU83bldOWXV0am9zajhDcWQwZlFYNW8?oc=5","date":"2023-12-18","type":"pipeline","source":"Business Wire","summary":"Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants - Business Wire","headline":"Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPOTRrZGZDVmdsY0ozWHhYYTQ0c1JESnprTTljQzFQLXRsbFJsalFKVVdVbjRpMndPeHRpQ0pvdzM4dnNMUGFqMi1xVkVfR2x1eFRXZERIajktcFhHVEltNXlXbUZhWFU3Vk53SEgtMWU5bkdZY1pfbXFYWWZKN0NWVGltTTN6RF9GWWRwSy1UOWdneUh6ZGI5c0d5LW5kZ25Ec0VQQWVLaEpSOERCb3RuXzJsVlhxdl9UYm9sODJuSF80UXNqZEVHSHp5UVhzX3JraVFYLWQxOGtKb1k1enk4?oc=5","date":"2022-09-16","type":"deal","source":"Business Wire","summary":"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement - Business Wire","headline":"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQbU1JMEVFWEwxQTNuZ3hfNFh0cXZ4T1NzTTlZcERtWW42dGNTZlQtR0V2YWpuaENiOHlLNFJ3VkI3VUNyNTV1TW9LQ25WTWRZSDAzMHpxZkhoTzl3ajZsMFpGd0poQUdFZlpFSjNLTEtVUnJaZHVLV29BbWQ4U2JmZXI1MFAyRVNtd1FZ?oc=5","date":"2022-07-05","type":"deal","source":"Yahoo Finance","summary":"TYME Technologies Shares Surge On Merger Agreement With Syros Pharma - Yahoo Finance","headline":"TYME Technologies Shares Surge On Merger Agreement With Syros Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQcjNFa1RJRDN3UE1rQXZnUUFXcC1rdUhQSUNJcHA4QVc4SFFrYjJ3WmlDdmxXN3lUSGVVX0ZtUFBsYzRBc2o3R2FOZzVXQVBoY1YxQmUyNGgyOU9XRkZVOEtpVm5iVmJSWEtBVFBzdURUWHMwaVBkRDRJUnU4T0ZEdWNCeXhubHROZnBhMGRGR011RnNYLXVtV2pwWE9mT2dUa2ptMTB1dVZmNGhR?oc=5","date":"2022-07-05","type":"deal","source":"The Pharma Letter","summary":"Syros acquires TYME and announces $130 million private placement - The Pharma Letter","headline":"Syros acquires TYME and announces $130 million private placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE8yRV90LVBFaUhxWlZCTmQ0UkRleUdOTzd5OWI3V0NsX2R3QkFFS1BvaG13RDFsRVRCY3FDcjI0bHRRQTZER2pYb0Izd3VXUQ?oc=5","date":"2020-10-11","type":"deal","source":"Stock Titan","summary":"Latest SYRS News - Rege Nephro Acquires Tamibarotene-Related A... - Stock Titan","headline":"Latest SYRS News - Rege Nephro Acquires Tamibarotene-Related A...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1VNkNzaEhBdnVOeXV1YnJMWlBkZTJFWnp4bENmMHpaSUM0YkRUZE1KZTcyc1F4b3puYTA5blU5NnVCcERId2FRcjdRNlFMZ3hNbzQtcEFqbGE3dw?oc=5","date":"2016-08-15","type":"pipeline","source":"MarketBeat","summary":"Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis $SYRS - MarketBeat","headline":"Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis $SYRS","sentiment":"neutral"}],"patents":[{"drugName":"Tamoxifen","drugSlug":"tamoxifen","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Roche","Bristol-Myers Squibb"],"therapeuticFocus":["Oncology","Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":1982000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":1982000,"period":"2019-12-31"},{"value":508000,"period":"2019-12-31"},{"value":558000,"period":"2019-09-30"},{"value":462000,"period":"2019-06-30"},{"value":454000,"period":"2019-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":108153000,"rdSpendHistory":[{"period":"2023-12-31","value":108153000},{"period":"2022-12-31","value":111944000},{"period":"2021-12-31","value":99872000}],"sgaSpend":28282000,"operatingIncome":-126499000,"operatingIncomeHistory":[{"period":"2023-12-31","value":-126499000},{"period":"2022-12-31","value":-126363000},{"period":"2021-12-31","value":-99420000}],"netIncome":-164574000,"netIncomeHistory":[{"period":"2023-12-31","value":-164574000},{"period":"2022-12-31","value":-94654000},{"period":"2021-12-31","value":-86558000}],"eps":-5.81,"epsHistory":[{"period":"2023-12-31","value":-5.81},{"period":"2022-12-31","value":-7.49},{"period":"2021-12-31","value":-13.84}],"cash":139526000,"cashHistory":[{"period":"2023-12-31","value":139526000},{"period":"2022-12-31","value":167467000},{"period":"2021-12-31","value":92302000}],"totalAssets":168174000,"totalLiabilities":151512000,"totalDebt":62075000,"equity":16662000,"operatingCashflow":-109707000,"operatingCashflowHistory":[{"period":"2023-12-31","value":-109707000},{"period":"2022-12-31","value":-123065000},{"period":"2021-12-31","value":-99540000}],"capex":-272000,"capexHistory":[{"period":"2023-12-31","value":-272000},{"period":"2022-12-31","value":-1241000},{"period":"2021-12-31","value":-1245000}],"freeCashflow":-109979000,"dividendsPaid":null,"buybacks":0,"employees":68,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5655000,"ebit":-5084000,"ebitda":-4759000,"period":"2024-09-30","revenue":0,"epsBasic":-0.16,"netIncome":-6396000,"rdExpense":20527000,"epsDiluted":-0.16,"grossProfit":null,"operatingIncome":-26182000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0,"previousClose":0,"fiftyTwoWeekHigh":0.04,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"1.0E-4 - 0.04","fiftyDayAverage":0,"twoHundredDayAverage":0,"beta":1.26,"enterpriseValue":1956366,"forwardPE":0,"priceToBook":0,"priceToSales":0.01,"enterpriseToRevenue":5.07,"enterpriseToEbitda":-0.02,"pegRatio":0,"ebitda":-110180000,"ebitdaMargin":0,"freeCashflow":-57942500,"operatingCashflow":-100016000,"totalDebt":60226000,"debtToEquity":0,"currentRatio":2.25,"returnOnAssets":-59.9,"returnOnEquity":-777,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":8.75,"targetHighPrice":20,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":9.6,"sharesOutstanding":26832457,"floatShares":26817699,"sharesShort":939583,"shortRatio":0.8,"shortPercentOfFloat":3.5,"epsTrailing":-3.07,"epsForward":-2.61,"revenuePerShare":0.01,"bookValue":-0.41,"officers":[{"age":53,"name":"Dr. James E. Bradner M.D.","title":"Founder"},{"age":null,"name":"Dr. Nathanael S. Gray Ph.D.","title":"Scientific Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Matthew  Foster","title":"Chief Restructuring Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.syros.com","phone":"617 744 1340"}}